Advanced Medical Solutions Group’s (AMS) “Buy” Rating Reaffirmed at Berenberg Bank

Berenberg Bank reissued their buy rating on shares of Advanced Medical Solutions Group (LON:AMS) in a research note released on Wednesday morning, Marketbeat.com reports. The firm currently has a GBX 300 target price on the stock.

Advanced Medical Solutions Group Price Performance

AMS stock opened at GBX 197.80 on Wednesday. The firm has a market capitalization of £428.01 million, a P/E ratio of 47.43, a price-to-earnings-growth ratio of 5.00 and a beta of 0.60. The firm has a 50 day moving average of GBX 212.50 and a 200-day moving average of GBX 214.38. Advanced Medical Solutions Group has a 12 month low of GBX 168.40 and a 12 month high of GBX 248.50. The company has a current ratio of 2.88, a quick ratio of 4.58 and a debt-to-equity ratio of 32.15.

Advanced Medical Solutions Group (LON:AMS) last released its quarterly earnings data on Wednesday, March 18th. The company reported GBX 11.98 earnings per share for the quarter. Advanced Medical Solutions Group had a net margin of 4.16% and a return on equity of 3.69%. As a group, sell-side analysts predict that Advanced Medical Solutions Group will post 9.8159509 earnings per share for the current fiscal year.

About Advanced Medical Solutions Group

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label.